Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: Therapeutic expression of factor IX at reduced vector doses

Human Gene Therapy

Volumn 21, Issue 3, 2010, Pages 271-283

  Jayandharan, Giridhara R ^a   Zhong, Li ^a,b   Sack, Brandon K ^a   Rivers, Angela E ^a   Li, Mengxin ^a   Li, Baozheng ^a   Herzog, Roland W ^a   Srivastava, Arun ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; HELPER VIRUS VECTOR; PARVOVIRUS VECTOR; PHOSPHOPROTEIN PHOSPHATASE; PREALBUMIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSDUCTION; HELPER VIRUS; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; ROUS SARCOMA ONCOVIRUS; SEROTYPE; TRANSGENE; VIRUS CAPSID; VIRUS MUTANT; WILD TYPE;

ANIMALS; DEPENDOVIRUS; DNA, SINGLE-STRANDED; FACTOR IX; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HELPER VIRUSES; HEPATOCYTES; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER; MALE; MICE; MICE, INBRED C57BL; NUCLEAR PROTEINS; PHOSPHOPROTEIN PHOSPHATASES; PREALBUMIN; PROMOTER REGIONS, GENETIC; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 2; TRANSDUCTION, GENETIC; TRANSGENES;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS - 2; MIRIDAE; MURINAE; ROUS SARCOMA VIRUS;

EID: 77949674544     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.100     Document Type: Article

References (65)

1. Aitken, M.L., Moss, R.B., Waltz, D.A., Dovey, M.E., Tonelli, M.R., McNamara, S.C., Gibson, R.L., Ramsey, B.W., Carter, B.J., and Reynolds, T.C. (2001). A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum. Gene Ther. 12, 1907-1916.
2. Akache, B., Grimm, D., Pandey, K., Yant, S.R., Xu, H., and Kay, M.A. (2006). The 37=67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J. Virol. 80, 9831-9836.
3. Auricchio, A., Hildinger, M., O'Connor, E., Gao, G.P., and Wilson, J.M. (2001). Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum. Gene Ther. 12, 71-76.
4. Bartlett, J.S., Wilcher, R., and Samulski, R.J. (2000). Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J. Virol. 74, 2777-2785.
5. Chen, S.J., Tazelaar, J., and Wilson, J.M. (2001). Selective re-population of normal mouse liver by hepatocytes transduced in vivo with recombinant adeno-associated virus. Hum. Gene Ther. 12, 45-50.
6. Conlon, T.J., and Flotte, T.R. (2004). Recombinant adeno-associated virus vectors for gene therapy. Expert Opin. Biol. Ther. 4, 1093-1101.
7. 1-antitrypsin vector. Mol. Ther. 12, 867-875.
8. Duan, D., Li, Q., Kao, A.W., Yue, Y., Pessin, J.E., and Engelhardt, J.F. (1999). Dynamin is required for recombinant adeno-associated virus type 2 infection. J. Virol. 73, 10371-10376.
9. Duan, D., Yue, Y., Yan, Z., Yang, J., and Engelhardt, J.F. (2000). Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J. Clin. Invest. 105, 1573-1587.
10. Ferrari, F.K., Samulski, T., Shenk, T., and Samulski, R.J. (1996). Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70, 3227-3234.
11. Fisher, K.J., Gao, G.P., Weitzman, M.D., Dematteo, R., Burda, J.F., and Wilson, J.M. (1996). Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J. Virol. 70, 520-532.
12. Flotte, T., Carter, B., Conrad, C., Guggino, W., Reynolds, T., Rosenstein, B., Taylor, G., Walden, S., and Wetzel, R. (1996). A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum. Gene Ther. 7, 1145-1159.
13. 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum. Gene Ther. 15, 93-128.
14. Gao, G.P., Alvira, M.R., Wang, L., Calcedo, R., Johnston, J., and Wilson, J.M. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99, 11854-11859.
15. Gao, G.P., Lu, Y., Sun, X., Johnston, J., Calcedo, R., Grant, R., and Wilson, J.M. (2006). High-level transgene expression in non-human primate liver with novel adeno-associated virus sero-types containing self-complementary genomes. J. Virol. 80, 6192-6194.
16. Grieger, J.C., and Samulski, R.J. (2005). Packaging capacity of adeno-associated virus serotypes: Impact of larger genomes on infectivity and postentry steps. J. Virol. 79, 9933-9944.
17. Hansen, J., Qing, K., Kwon, H.J., Mah, C., and Srivastava, A. (2000). Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J. Virol. 74, 992-996.
18. Hansen, J., Qing, K., and Srivastava, A. (2001a). Adeno-associated virus type 2-mediated gene transfer: Altered endocytic processing enhances transduction efficiency in murine fibroblasts. J. Virol. 75, 4080-4090.
19. Hansen, J., Qing, K., and Srivastava, A. (2001b). Infection of purified nuclei by adeno-associated virus 2. Mol. Ther. 4, 289-296.
20. Hinds, T.D., Jr., and Sanchez, E.R. (2008). Protein phosphatase 5. Int. J. Biochem. Cell Biol. 40, 2358-2362.
21. Jayandharan, G.R., Zhong, L., Li, B., Kachniarz, B., and Srivas-tava, A. (2008). Strategies for improving the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther. 15, 1287-1293.
22. Jiang, H., Lillicrap, D., Patarroyo-White, S., Liu, T., Qian, X., Scallan, C.D., Powell, S., Keller, T., McMurray, M., Labelle, A., Nagy, D., Vargas, J.A., Zhou, S., Couto, L.B., and Pierce, G.F. (2006). Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 108, 107-115.
23. Kashiwakura, Y., Tamayose, K., Iwabuchi, K., Hirai, Y., Shima-da, T., Matsumoto, K., Nakamura, T., Watanabe, M., Oshimi, K., and Daida, H. (2005). Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J. Virol. 79, 609-614.
24. Kay, M.A., Manno, C.S., Ragni, M.V., Larson, P.J., Couto, L.B., McClelland, A., Glader, B., Chew, A.J., Tai, S.J., Herzog, R.W., Arruda, V., Johnson, F., Scallan, C., Skarsgard, E., Flake, A.W., and High, K.A. (2000). Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24, 257-261.
25. Kube, D.M., and Srivastava, A. (1997). Quantitative DNA slot blot analysis: Inhibition of DNA binding to membranes by magnesium ions. Nucleic Acids Res. 25, 3375-3376.
26. Liao, L., Dearth, R.K., Zhou, S., Britton, O.L., Lee, A.V., and Xu, J. (2006). Liver-specific overexpression of the insulin-like growth factor-I enhances somatic growth and partially prevents the effects of growth hormone deficiency. Endocrinology 147, 3877-3888.
27. Mah, C., Qing, K., Khuntirat, B., Ponnazhagan, S., Wang, X.S., Kube, D.M., Yoder, M.C., and Srivastava, A. (1998). Adeno-associated virus type 2-mediated gene transfer: Role of epidermal growth factor receptor protein tyrosine kinase in transgene expression. J. Virol. 72, 9835-9843.
28. Manno, C.S., Chew, A.J., Hutchison, S., Larson, P.J., Herzog, R.W., Arruda, V.R., Tai, S.J., Ragni, M.V., Thompson, A., Ozelo, M., Couto, L.B., Leonard, D.G., Johnson, F.A., McClelland, A., Scallan, C., Skarsgard, E., Flake, A.W., Kay, M.A., High, K.A., and Glader, B. (2003). AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101, 2963-2972.
29. Marshall, E. (2001). Gene therapy: Viral vectors still pack surprises. Science 294, 1640.
30. McCarty, D.M., Monahan, P.E., and Samulski, R.J. (2001). Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 8, 1248-1254.
31. Mingozzi, F., Liu, Y.L., Dobrzynski, E., Kaufhold, A., Liu, J.H., Wang, Y., Arruda, V.R., High, K.A., and Herzog, R.W. (2003). Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin. Invest. 111, 1347-1356.
32. \+ T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13, 419-422.
33. Muzyczka, N. (1992). Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Micro-biol. Immunol. 158, 97-129.
34. Nakai, H., Storm, T.A., and Kay, M.A. (2000). Increasing the size of rAAV-mediated expression cassettes in vivo by intermo-lecular joining of two complementary vectors. Nat. Biotechnol. 18, 527-532.
35. Petry, H., Brooks, A., Orme, A., Wang, P., Liu, P., Xie, J., Kretschmer, P., Qian, H.S., Hermiston, T.W., and Harkins, R.N. (2008). Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice. Gene Ther. 15, 54-60.
36. Ponnazhagan, S., Mukherjee, P., Yoder, M.C., Wang, X.S., Zhou, S.Z., Kaplan, J., Wadsworth, S., and Srivastava, A. (1997). Adeno-associated virus 2-mediated gene transfer in vivo: Organ-tropism and expression of transduced sequences in mice. Gene 190, 203-210.
37. Qing, K., Wang, X.S., Kube, D.M., Ponnazhagan, S., Bajpai, A., and Srivastava, A. (1997). Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression. Proc. Natl. Acad. Sci. U.S.A. 94, 10879-10884.
38. Qing, K., Khuntirat, B., Mah, C., Kube, D.M., Wang, X.S., Pon-nazhagan, S., Zhou, S., Dwarki, V.J., Yoder, M.C., and Sri-vastava, A. (1998). Adeno-associated virus type 2-mediated gene transfer: Correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo. J. Virol. 72, 1593-1599.
39. Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., and Sri-vastava, A. (1999). Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 5, 71-77.
40. Qing, K., Hansen, J., Weigel-Kelley, K.A., Tan, M., Zhou, S., and Srivastava, A. (2001). Adeno-associated virus type 2-mediated gene transfer: Role of cellular FKBP52 protein in transgene expression. J. Virol. 75, 8968-8976.
41. Qing, K., Li, W., Zhong, L., Tan, M., Hansen, J., Weigel-Kelley, K.A., Chen, L., Yoder, M.C., and Srivastava, A. (2003). Adeno-associated virus type 2-mediated gene transfer: Role of cellular T-cell protein tyrosine phosphatase in transgene expression in established cell lines in vitro and transgenic mice in vivo. J. Virol. 77, 2741-2746.
42. Sanlioglu, S., Benson, P.K., Yang, J., Atkinson, E.M., Reynolds, T., and Engelhardt, J.F. (2000). Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J. Virol. 74, 9184-9196.
43. Sarkar, R., Xiao, W., and Kazazian, H.H., Jr. (2003). A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype. J. Thromb. Hae-most. 1, 220-226.
44. Scallan, C.D., Lillicrap, D., Jiang, H., Qian, X., Patarroyo-White, S.L., Parker, A.E., Liu, T., Vargas, J., Nagy, D., Powell, S.K., Wright, J.F., Turner, P.V., Tinlin, S.J., Webster, S.E., McClelland, A., and Couto, L.B. (2003). Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. Blood 102, 2031-2037.
45. Seisenberger, G., Ried, M.U., Endress, T., Buning, H., Hallek, M., and Brauchle, C. (2001). Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science 294, 1929-1932.
46. Snyder, R.O., and Francis, J. (2005). Adeno-associated viral vectors for clinical gene transfer studies. Curr. Gene Ther. 5, 311-321.
47. Snyder, R.O., Miao, C.H., Patijn, G.A., Spratt, S.K., Danos, O., Nagy, D., Gown, A.M., Winther, B., Meuse, L., Cohen, L.K.,Thompson, A.R., and Kay, M.A. (1997). Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet. 16, 270-276.
48. Song, S., Embury, J., Laipis, P.J., Berns, K.I., Crawford, J.M., and Flotte, T.R. (2001). Stable therapeutic serum levels of human a-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 8, 1299-1306.
49. Summerford, C., and Samulski, R.J. (1998). Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438-1445.
50. 5 integrin: A co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5, 78-82.
51. Thomas, C.E., Storm, T.A., Huang, Z., and Kay, M.A. (2004). Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J. Virol. 78, 3110-3122.
52. Vandenberghe, L.H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R.A., Chen, C.S., Johnston, J., Grant, R.L., Gao, G., and Wilson, J.M. (2006). Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat. Med. 12, 967-971.
53. Wagner, J.A., Nepomuceno, I.B., Messner, A.H., Moran, M.L., Batson, E.P., Dimiceli, S., Brown, B.W., Desch, J.K., Norbash, A.M., Conrad, C.K., Guggino, W.B., Flotte, T.R., Wine, J.J., Carter, B.J., Reynolds, T.C., Moss, R.B., and Gardner, P. (2002). A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum. Gene Ther. 13, 1349-1359.
54. Wang, L., Calcedo, R., Nichols, T.C., Bellinger, D.A., Dillow, A., Verma, I.M., and Wilson, J.M. (2005). Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2=8-mediated, liver-directed gene therapy. Blood 105, 3079-3086.
55. Wang, X.S., Qing, K., Ponnazhagan, S., and Srivastava, A. (1997). Adeno-associated virus type 2 DNA replication in vivo: Mutation analyses of the D sequence in viral inverted terminal repeats. J. Virol. 71, 3077-3082.
56. Wang, Z., Ma, H.I., Li, J., Sun, L., Zhang, J., and Xiao, X. (2003). Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther. 10, 2105-2111.
57. Wu, J., Zhao, W., Zhong, L., Han, Z., Li, B., Ma, W., Weigel-Kelley, K.A., Warrington, K.H., and Srivastava, A. (2007). Self-complementary recombinant adeno-associated viral vectors: Packaging capacity and the role of Rep proteins in vector purity. Hum. Gene Ther. 18, 171-182.
58. Wu, Z., Sun, J., Zhang, T., Yin, C., Yin, F., Van Dyke, T., Samulski, R.J., and Monahan, P.E. (2008). Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol. Ther. 16, 280-289.
59. Zhao, W., Zhong, L., Wu, J., Chen, L., Qing, K., Weigel-Kelley, K.A., Larsen, S.H., Shou, W., Warrington, K.H., Jr., and Sri-vastava, A. (2006). Role of cellular FKBP52 protein in intra-cellular trafficking of recombinant adeno-associated virus 2 vectors. Virology 353, 283-293.
60. Zhao, W., Wu, J., Zhong, L., and Srivastava, A. (2007). Adeno-associated virus 2-mediated gene transfer: Role of a cellular serine=threonine protein phosphatase in augmenting trans-duction efficiency. Gene Ther. 14, 545-550.
61. Zhong, L., Chen, L., Li, Y., Qing, K., Weigel-Kelley, K.A., Chan, R.J., Yoder, M.C., and Srivastava, A. (2004a). Self-complementary adeno-associated virus 2 (AAV)-T cell protein tyrosine phosphatase vectors as helper viruses to improve transduction efficiency of conventional single-stranded AAV vectors in vitro and in vivo. Mol. Ther. 10, 950-957.
62. Zhong, L., Li, W., Yang, Z., Chen, L., Li, Y., Qing, K., Weigel-Kelley, K.A., Yoder, M.C., Shou, W., and Srivastava, A. (2004b). Improved transduction of primary murine hepato-cytes by recombinant adeno-associated virus 2 vectors in vivo. Gene Ther. 11, 1165-1169.
63. Zhong, L., Li, W., Yang, Z., Qing, K., Tan, M., Hansen, J., Li, Y., Chen, L., Chan, R.J., Bischof, D., Maina, N., Weigel-Kelley, K.A., Zhao, W., Larsen, S.H., Yoder, M.C., Shou, W., and Srivastava, A. (2004c). Impaired nuclear transport and un-coating limit recombinant adeno-associated virus 2 vector-mediated transduction of primary murine hematopoietic cells. Hum. Gene Ther. 15, 1207-1218.
64. Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., Muzyczka, N., and Srivas-tava, A. (2008a). Tyrosine- phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 381, 194-202.
65. Zhong, L., Li, B., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R.W., Zolotukhin, I., Warrington, K.H., Jr., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., Muzyczka, N., and Srivastava, A. (2008b). Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. U.S.A. 105, 7827-7832.